Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SMTI 
Sanara Medtech Inc (SMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: SMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $50
1 Year Target Price $50
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.7% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 260.84M USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 2 | Beta 1.21 | 52 Weeks Range 23.53 - 39.08 | Updated Date 10/31/2025 |
52 Weeks Range 23.53 - 39.08 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.22% | Operating Margin (TTM) -0.12% |
Management Effectiveness
Return on Assets (TTM) -2.5% | Return on Equity (TTM) -26.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 303396741 | Price to Sales(TTM) 2.68 |
Enterprise Value 303396741 | Price to Sales(TTM) 2.68 | ||
Enterprise Value to Revenue 3.12 | Enterprise Value to EBITDA 2065.65 | Shares Outstanding 8902351 | Shares Floating 3579012 |
Shares Outstanding 8902351 | Shares Floating 3579012 | ||
Percent Insiders 65.56 | Percent Institutions 12.4 |
Upturn AI SWOT
Sanara Medtech Inc
Company Overview
History and Background
Sanara MedTech Inc., formerly known as Wound Management Technologies, was founded in 2011. It focuses on developing, marketing, and distributing wound and skin care products.
Core Business Areas
- Wound and Skin Care Products: Develops, markets, and distributes advanced wound and skin care products for use by physicians and patients in hospitals, clinics, and at home.
Leadership and Structure
Ron Nixon serves as the Executive Chairman of the Board, and Zachary Fleming is the Chief Executive Officer. The company operates with a typical corporate structure including departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- BIAKu014cSu2122 Antimicrobial Skin and Wound Cleanser: An antimicrobial skin and wound cleanser designed to help prevent infection. Revenue data not publicly specified. Competitors include Mu00f6lnlycke Health Care (private), Smith+Nephew (SNN), and ConvaTec (CTEC).
- CellerateRXu00ae Surgical Matrix: A collagen-based surgical matrix to promote tissue repair. Revenue data not publicly specified. Competitors include Integra LifeSciences (IART), ACell (private), and Organogenesis (ORGO).
Market Dynamics
Industry Overview
The wound care market is growing due to the aging population, increasing incidence of chronic diseases like diabetes, and rising demand for advanced wound care products.
Positioning
Sanara Medtech is positioned as a player focused on innovative wound and skin care solutions, with products designed to address unmet needs in the market. They are smaller compared to major medical device corporations but maintain a niche.
Total Addressable Market (TAM)
The global wound care market is expected to reach over $22 billion by 2028. Sanara Medtech is positioned to capture a portion of this growing market with its focus on advanced wound care solutions. Penetration of TAM is low but growing.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Focus on advanced wound care
- Experienced management team
- Strategic acquisitions
Weaknesses
- Small market capitalization
- Limited brand recognition compared to larger competitors
- Dependence on a few key products
- Profitability issues
Opportunities
- Expanding product line
- Increasing penetration of existing products
- Strategic partnerships and acquisitions
- Growing wound care market
Threats
- Competition from larger players
- Regulatory changes
- Pricing pressure
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Smith+Nephew (SNN)
- Integra LifeSciences (IART)
- Organogenesis (ORGO)
Competitive Landscape
Sanara Medtech faces significant competition from larger, more established players in the wound care market. Sanara Medtech's strengths lie in niche products and strategic acquisitions, while its weaknesses include smaller scale and limited brand awareness.
Major Acquisitions
Hydrus Technology
- Year: 2020
- Acquisition Price (USD millions): 6.5
- Strategic Rationale: Expanded product portfolio with innovative wound care technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by product sales and acquisitions. Volatile revenue due to acquisition timing and organic growth variances.
Future Projections: Future growth will depend on the successful launch of new products, increased market penetration, and strategic acquisitions. No analyst estimates provided.
Recent Initiatives: Recent initiatives include the development and launch of new wound care products and continued expansion into new markets through strategic partnerships.
Summary
Sanara Medtech focuses on a high-growth niche but faces challenges from larger competitors. Their innovative product development and strategic acquisitions are positive signals. However, consistent profitability remains a concern. Improving brand recognition and market penetration are critical for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Industry reports
- Financial databases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data is based on available information and may not be completely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanara Medtech Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2011-02-22 | President, CEO & Director Mr. Seth D. Yon | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 141 | Website https://sanaramedtech.com |
Full time employees 141 | Website https://sanaramedtech.com | ||
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.